# MiNA Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mina-therapeutics

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.minatx.com
- Total disclosed funding: $27M
- Latest round: Series A (Sep 10, 2020)
- Investors on record: 1

## About

MiNA Therapeutics Limited is a biotechnology company dedicated to developing small activating RNA therapeutics (RNAa) that enhance gene function to address various diseases.Founded in 2008 and headquartered in London, UK, MiNA Therapeutics Limited specializes in RNAa therapeutics aimed at restoring normal cellular pathways. The company has undergone no significant pivots and operates independently. CEO Robert Habib leads the company, which has successfully raised GBP 11 million in venture funding in June 2021 from Eli Lilly & Company, bringing the total amount raised to GBP 11 million with a current valuation of GBP 158.61 million.MiNA Therapeutics focuses on developing small activating RNA therapeutics (RNAa) designed to enhance gene function and restore cellular pathways. Their flagship RNAa medicine has been evaluated in clinical trials with over 130 patients, showing proof of concept for their platform. The company collaborates with pharmaceutical partners and research institutions primarily in North America and Europe to extend the application of their technology across various therapeutic areas.In 2022, MiNA Therapeutics reported zero revenue with an EBITDA of GBP -30,536,386.70, generating revenue through strategic partnerships and collaborations for the development and commercialization of RNAa therapeutics.Following the GBP 11 million funding secured in June 2021 from Eli Lilly & Company, MiNA Therapeutics plans to advance and expand its pipeline of small activating RNA therapeutics. The company aims to introduce new products targeting genetic disorders and is looking to expand its reach in North America and Europe. This funding will support the continued development of their lead product for sickle cell disease and facilitate further clinical trials.

## Funding rounds

- Series A, Sep 10, 2020, $27M — aMoon

## Investors

- aMoon (https://capitalatlas.ai/funds/amoon) — Series A